AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

652.248

-33.700-4.91%

Number of Gainers:11

Number of Losers:16

Number of Flat:18

PE:- -

High:653.304

Open:623.278

Low:609.051

Close:685.948

Volume:55.12M

Turnover:524.96M

Market Cap:89.43B

Float Cap:86.30B

Loading ...

Neuren Pharmaceuticals to Commence New On-Market Share Buy-Back Program

MT Newswires Live

Australian shares reclaim 9,000 mark as banks rally on CBA results

GLOBAL MARKETS-Buoyant stocks pause for breath; yen gallops higher

Neuren Pharmaceuticals - Buy-Back Program Will Not Exceed 5% of Total Shares on Issue 12 Months Prior to Commencement of Buy- Back

THOMSON REUTERS

CSL's Fiscal H1 EBIT Boosted by Cost Reductions, Jarden Says

MT Newswires Live

ASX Midday Sector Update: Financial Shares Jump, Healthcare Shares Fall

MT Newswires Live

Bioxyne Secures Initial Purchase Orders for Psychedelic Drug; Shares Rise 7%

MT Newswires Live

BRIEF-Bioxyne Commercialises GMP-Manufactured Psilocybin Capsules

Australian shares rise in earnings-heavy session; CSL plunges 18%

Paradigm Says Study Evaluating Lead Product in Canine Arthritis Show Sustained Reductions in Chronic Pain

MT Newswires Live

BUZZ-Australia's CSL tumbles to near 8-year low after CEO retires, HY profit slips

Racura Oncology Develops Blood Test to Assess Potential of Proprietary Formulation of Anticancer Drug

MT Newswires Live

Australian biotech firm CSL tanks 17% after CEO departure, weak first-half earnings

Former 'market-darling' CSL dumps CEO as it reports results

Bioxyne Ltd - Commercialises Gmp-Manufactured Psilocybin Capsules

THOMSON REUTERS

Australia's CSL posts a 7% drop in first-half profit

BRIEF-CSL Declares Interim Dividend Of $1.30 Per Share

CSL Ltd - Performance of CSL Vifor Will Continue to Be Adversely Impacted by Generic Competition in Iron Products

THOMSON REUTERS

CSL Ltd - CSL Behring, Second-Half Growth Is Expected to Be Driven by Ig, Albumin and Newly Launched Products

THOMSON REUTERS

CSL Ltd - Share Buy-Back Expanded From US$500M to US$750M

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":652.2475,"timestamp":1770785999863,"preClose":685.9476,"halted":0,"volume":55120552,"delay":0,"changeRate":-0.049129,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-33.700073,"latestTime":"02-11 16:00:00 AEDT","open":623.27826,"high":653.304,"low":609.0506,"amount":524961409,"amplitude":0.064514,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770850800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1770764400000,1770786000000]],"turnoverRate":0.002117,"increases":13,"decrements":16,"flats":15,"marketCap":89434062142.75,"floatMarketCap":86298762532.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":653.304,"amplitude":0.064514,"preClose":685.9476,"low":609.0506,"latestPrice":652.2475,"volume":55120552,"delay":0,"open":623.27826,"prevYearClose":644.3692,"prevWeekClose":670.691,"prevMonthClose":674.161,"prevQuarterClose":644.369,"fiveDayClose":678.235,"twentyDayClose":646.984,"sixtyDayClose":662.596,"secType":"PLATE","market":"AU","turnoverRate":0.002117,"marketCap":89434062142.75,"floatMarketCap":86298762532.5,"timestamp":1770785999863,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":11,"down":16,"flat":18},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610983756","title":"Neuren Pharmaceuticals to Commence New On-Market Share Buy-Back Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2610983756","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610983756?lang=en_us&edition=fundamental","pubTime":"2026-02-11 14:47","pubTimestamp":1770792440,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  disclosed a new on-market share buy-back program with a period of up to 12 months, which will be conducted under section 65 of the New Zealand Companies Act 1993 and will not exceed 5% of the total shares on issue 12 months before the commencement of the buy-back, according to a Wednesday Australian bourse filing.\"The board views the current share price as materially undervaluing Neuren's assets, relative to internal analyses and the range of recently published analyst valuations,\" said Chair Patrick Davies.Shares purchased under the buy-back will be cancelled upon acquisition, reducing the number of shares on issue, and the number of shares purchased under the buy-back will be less than the \"10/12\" limit prescribed in the Australian Corporations Act and will not require shareholder approval, the filing added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2610983995","title":"Australian shares reclaim 9,000 mark as banks rally on CBA results","url":"https://stock-news.laohu8.com/highlight/detail?id=2610983995","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610983995?lang=en_us&edition=fundamental","pubTime":"2026-02-11 14:34","pubTimestamp":1770791642,"startTime":"0","endTime":"0","summary":"Australian shares reclaim 9,000 mark as banks rally on CBA resultsCBA up 6.8%Domino's Pizza Enterprises jump 2.9%AGL Energy up 11.8%Healthcare stocks log lowest level since mid-May 2019By Anjali  Singh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL6N3Z705K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","IE0004445015.USD","IE00BJJMRY28.SGD","BK7508","LU0868494708.USD","LU0726765562.USD","LU1244550494.USD","LU0868494617.USD","IE00BFSS7M15.SGD","AGL.AU","LU1244550577.SGD","MCD","NAB.AU","IE00BJTD4N35.SGD","BK7137","CBA.AU","BK4585","LU0795875169.SGD","LU1074936037.SGD","BK4534","LU0256863811.USD","LU1732799900.SGD","LU2279689827.SGD","LU2133065610.SGD","BK7067","IE00BFSS8Q28.SGD","LU0795875086.SGD","BK4581","LU1244550221.USD","LU0912757837.SGD","LU0942090050.USD","BK7135","BK7136","ANZ.AU","LU0417517546.SGD","WBC.AU","BK4504","AN3PL.AU","BK7501","LU1035773651.USD","DMP.AU","LU1585245621.USD","BK4588","LU1430594728.SGD","LU1718418525.SGD","LU2347655156.SGD","BK4610","BK4550","LU1732800096.USD","IE00BJJMRX11.SGD"],"gpt_icon":0},{"id":"2610698834","title":"GLOBAL MARKETS-Buoyant stocks pause for breath; yen gallops higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2610698834","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610698834?lang=en_us&edition=fundamental","pubTime":"2026-02-11 14:02","pubTimestamp":1770789744,"startTime":"0","endTime":"0","summary":"GLOBAL MARKETS-Buoyant stocks pause for breath; yen gallops higherYen up 2.5% vs dollar since Japan electionCBA up; CSL dives as Aussie results season kicks offS&P 500 futures steady; US jobs data awaitedUpdates to Asia afternoonBy Tom Westbrook. SINGAPORE, Feb 11  - Bonds gained and a rebound in stock markets slowed down on Wednesday after softer-than-expected U.S. retail sales figures, while a rally in the yen has extended and might be beginning to signal a shift in investor thinking since Japan's election.U.S. jobs figures are due later in the day and the chance of downward revisions to recent numbers have pressured the dollar.Trade in Asia was lightened by a holiday in Japan, but a third straight session of gains for the yen JPY= had it at 153.3 per dollar and set traders talking about whether it was catching a boost from Tokyo or riding high on dollar softness.It is up about 2.5% on the dollar since Prime Minister Sanae Takaichi won a sweeping victory in Sunday's election, confoun","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL1N3Z704U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7067","BK7508","BK7511","BK7135","CBA.AU","BK7501"],"gpt_icon":0},{"id":"2610988807","title":"Neuren Pharmaceuticals -  Buy-Back Program Will Not Exceed 5% of Total Shares on Issue 12 Months Prior to Commencement of Buy- Back","url":"https://stock-news.laohu8.com/highlight/detail?id=2610988807","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610988807?lang=en_us&edition=fundamental","pubTime":"2026-02-11 14:00","pubTimestamp":1770789635,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z61NR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","NEU.AU"],"gpt_icon":0},{"id":"2610601753","title":"CSL's Fiscal H1 EBIT Boosted by Cost Reductions, Jarden Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2610601753","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610601753?lang=en_us&edition=fundamental","pubTime":"2026-02-11 11:39","pubTimestamp":1770781183,"startTime":"0","endTime":"0","summary":"CSL's  fiscal first-half earnings before interest and taxes  were boosted by big reductions in research and development as well as and general and administrative expenses, meeting expectations, Jarden said in a note on Wednesday.The company reported fiscal first-half underlying earnings of $4.03 per share, down from $4.29 a year earlier. Revenue for the six months ended Dec. 31, 2025, was $8.33 billion, compared with $8.48 billion a year earlier.The company maintained its fiscal 2026 guidance of a 2% to 3% growth in revenue and a 4% to 7% growth in net profit after tax and amortization.Fears around big downgrades were heightened after the surprise forced retirement of Chief Executive Paul McKenzie before the company reaffirmed guidance.There are good reasons to expect a recovery in IG and Albumin in the second fiscal half with Medicare Part D funding impact now in base and new Albumin distribution agreement starting.The investment firm reaffirmed an overweight rating with a price targe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LU1169590202.USD","CSL.AU","BK4086","BK7511","BK7501","SG9999004303.SGD","SGXZ23171101.USD","LU0728928796.USD","LU1169589451.USD","EBIT","CSL","BK7508"],"gpt_icon":0},{"id":"2610606258","title":"ASX Midday Sector Update: Financial Shares Jump, Healthcare Shares Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2610606258","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610606258?lang=en_us&edition=fundamental","pubTime":"2026-02-11 10:25","pubTimestamp":1770776757,"startTime":"0","endTime":"0","summary":"Shares of financial firms jumped nearly 4% at midday Wednesday, boosted by earnings from the country's largest bank.Commonwealth Bank of Australia  reported fiscal first-half cash earnings of AU$3.252 per share, up from AU$3.065 a year earlier.The Bank also said an independent review confirmed that the outcomes achieved through its Prudential Inquiry Remedial Action Plan have been sustained.On the flip side, the healthcare sector fell 3%.CSL  reported Wednesday fiscal first-half underlying earnings of $4.03 per share, down from $4.29 a year earlier.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4581","LU0128526141.USD","LU0029874061.USD","XBI","BK4137","BK4585","CSL.AU","BK4588","XLV","BK7511","BK7135","BK7501","BK7508","LABU","HCSG","BK7067","CBA.AU"],"gpt_icon":0},{"id":"2610606323","title":"Bioxyne Secures Initial Purchase Orders for Psychedelic Drug; Shares Rise 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610606323","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610606323?lang=en_us&edition=fundamental","pubTime":"2026-02-11 10:00","pubTimestamp":1770775250,"startTime":"0","endTime":"0","summary":"Bioxyne  secured initial purchase orders for the supply of psilocybin capsules, or BLSPSIL25, through its wholly-owned unit Breathe Life Sciences, according to a Wednesday Australian bourse filing.The capsules are intended for investigational use in treatment-resistant depression and exploratory research into other mental health conditions in Australia, including anxiety disorders, substance use disorders, and post-traumatic stress disorder.These initial orders involve the supply of 250 doses of BLSPSIL25 to authorized prescribers in Queensland and Western Australia, supporting treatment for around 60 patients over the next 12 months.Bioxyne's shares rose nearly 7% in recent trading on Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BXN.AU","BK7508","BK7111","XKO.AU","XJO.AU","XAO.AU"],"gpt_icon":0},{"id":"2610605317","title":"BRIEF-Bioxyne Commercialises GMP-Manufactured Psilocybin Capsules","url":"https://stock-news.laohu8.com/highlight/detail?id=2610605317","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610605317?lang=en_us&edition=fundamental","pubTime":"2026-02-11 09:38","pubTimestamp":1770773911,"startTime":"0","endTime":"0","summary":"BRIEF-Bioxyne Commercialises GMP-Manufactured Psilocybin CapsulesFeb 11 (Reuters) - Bioxyne Ltd BXN.AX:COMMERCIALISES GMP-MANUFACTURED PSILOCYBIN CAPSULESFurther company coverage: BXN.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z61EQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7111","BXN.AU","BK7508"],"gpt_icon":0},{"id":"2610060818","title":"Australian shares rise in earnings-heavy session; CSL plunges 18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610060818","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610060818?lang=en_us&edition=fundamental","pubTime":"2026-02-11 08:31","pubTimestamp":1770769904,"startTime":"0","endTime":"0","summary":"Australian shares rise in earnings-heavy session; CSL plunges 18% Feb 11 (Reuters) - Australian shares advanced on Wednesday, led by gains in financials and miners as a series of earnings bolstered se","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL4N3Z700B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CBA.AU","BK4011","JHX","BK7135","AGL.AU","BK7501","CSL.AU","BK7136","BK7511","BK7508"],"gpt_icon":0},{"id":"2610187608","title":"Paradigm Says Study Evaluating Lead Product in Canine Arthritis Show Sustained  Reductions in Chronic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2610187608","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610187608?lang=en_us&edition=fundamental","pubTime":"2026-02-11 08:30","pubTimestamp":1770769806,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  said a study of its lead product, pentosan polysulfate sodium , in canine osteoarthritis showed sustained reductions in chronic pain and normalization of gait symmetry through 26 weeks, compared with placebo, according to a Wednesday filing with the Australian bourse.The study assesses the durability and potential disease-modifying effects of a six-week course of PPS in dogs with naturally occurring osteoarthritis of the stifle and/or elbow joints, the filing said.Following the treatment, magnetic resonance imaging and serum biomarker findings were consistent with slowed cartilage degradation and altered bone and cartilage turnover, the filing said.The study also provides a compressed analogue of longer-term human outcomes, the filing added.Shares of the company fell 1% in recent Wednesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7016","BK7503","PPS","PAR.AU","PPS.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2610677130","title":"BUZZ-Australia's CSL tumbles to near 8-year low after CEO retires, HY profit slips","url":"https://stock-news.laohu8.com/highlight/detail?id=2610677130","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610677130?lang=en_us&edition=fundamental","pubTime":"2026-02-11 07:29","pubTimestamp":1770766184,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's CSL tumbles to near 8-year low after CEO retires, HY profit slips** Shares of biotechnology giant CSL CSL.AX plunge 17.6% to A$151.350 in early trade, their lowest since mid-February ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nL6N3Z61CU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","CSL.AU","BK7508","BK7511"],"gpt_icon":0},{"id":"2610967768","title":"Racura Oncology Develops Blood Test to Assess Potential of Proprietary Formulation of Anticancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2610967768","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610967768?lang=en_us&edition=fundamental","pubTime":"2026-02-11 07:19","pubTimestamp":1770765542,"startTime":"0","endTime":"0","summary":"Racura Oncology  developed a blood-based molecular test to assess the potential of RC220, its proprietary formulation of bisantrene, a potent anticancer drug, to protect the heart from damage, according to a Wednesday filing with the Australian bourse.The blood test will quantify the protective effects of RC220 on the molecular pathways causing anthracycline cardiotoxicity, a side effect of chemotherapy, the filing said.Bisantrene has proven clinical efficacy in a range of solid tumor cancers with lower heart toxicity than other widely used chemotherapies, the company said in a statement.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","RAC.AU"],"gpt_icon":0},{"id":"2610677880","title":"Australian biotech firm CSL tanks 17% after CEO departure, weak first-half earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2610677880","media":"Reuters","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610677880?lang=en_us&edition=fundamental","pubTime":"2026-02-11 07:09","pubTimestamp":1770764970,"startTime":"0","endTime":"0","summary":"Feb 11  - Shares of Australia's CSL Ltd CSL.AX plunged more than 17% in early trading on Wednesday after the biotech giant announced the departure of its chief executive officer, Paul McKenzie, and reported a 7% drop in its first-half earnings.CSL's shares plunged 17.6% to A$151.350, their lowest since mid-February 2018.   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nL4N3Z62ME:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7501","BK7508","BK7067","CSL.AU"],"gpt_icon":0},{"id":"2610672638","title":"Former 'market-darling' CSL dumps CEO as it reports results","url":"https://stock-news.laohu8.com/highlight/detail?id=2610672638","media":"Switzer","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610672638?lang=en_us&edition=fundamental","pubTime":"2026-02-11 06:29","pubTimestamp":1770762570,"startTime":"0","endTime":"0","summary":"CSL’s board has moved to hit the reset button just hours before a crucial earnings report.","market":"us","thumbnail":"https://switzer.com.au/wp-content/uploads/CSL-HALF-YEAR-RESULTS.jpg","type":0,"news_type":0,"thumbnails":["https://switzer.com.au/wp-content/uploads/CSL-HALF-YEAR-RESULTS.jpg"],"rights":{"source":"switzer_stock","url":"https://switzer.com.au/the-experts/luke-hopewell/former-market-darling-csl-dumps-ceo-as-it-reports-results/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://switzer.com.au/the-experts/luke-hopewell/former-market-darling-csl-dumps-ceo-as-it-reports-results/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"switzer_stock","symbols":["LU1169590202.USD","SG9999004303.SGD","CSL","BK4086","BK7508","LU0728928796.USD","BK7511","BK7067","LU1169589451.USD","SGXZ23171101.USD","CSL.AU","BK7501"],"gpt_icon":0},{"id":"2610679384","title":"Bioxyne Ltd - Commercialises Gmp-Manufactured Psilocybin Capsules","url":"https://stock-news.laohu8.com/highlight/detail?id=2610679384","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610679384?lang=en_us&edition=fundamental","pubTime":"2026-02-11 05:18","pubTimestamp":1770758331,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nFWN3Z61EQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7111","BK7508","BXN.AU"],"gpt_icon":0},{"id":"2610675439","title":"Australia's CSL posts a 7% drop in first-half profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2610675439","media":"Reuters","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610675439?lang=en_us&edition=fundamental","pubTime":"2026-02-11 04:49","pubTimestamp":1770756545,"startTime":"0","endTime":"0","summary":"Australia's CSL posts a 7% drop in first-half profitFeb 11  - Australia's CSL Ltd CSL.AX reported a 7% fall in first-half profit, hit by softer plasma-therapy and albumin sales, while lifting its share buyback to $750 million. The biotechnology giant reported underlying net profit after tax attributable of $1.92 billion, on a constant currency basis, for the six months ended December 31, compared with $2.11 billion reported in the year-ago period.  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nL4N3Z62EA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","CSL.AU","BK7511","BK7501"],"gpt_icon":0},{"id":"2610267548","title":"BRIEF-CSL Declares Interim Dividend Of $1.30 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2610267548","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610267548?lang=en_us&edition=fundamental","pubTime":"2026-02-11 04:47","pubTimestamp":1770756468,"startTime":"0","endTime":"0","summary":"BRIEF-CSL Declares Interim Dividend Of $1.30 Per ShareFeb 11 (Reuters) - CSL Ltd CSL.AX:H1 NET INCOME USD 401 MILLION VERSUS. IBES ESTIMATE USD 1,936 MILLIONH1 ADJUSTED NET INCOME USD 1,900 MILLIONFY2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nPLX8AA1DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","BK7511","BK7508","CSL.AU"],"gpt_icon":0},{"id":"2610751146","title":"CSL Ltd - Performance of CSL Vifor Will Continue to Be Adversely Impacted by Generic Competition in Iron Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2610751146","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610751146?lang=en_us&edition=fundamental","pubTime":"2026-02-11 04:41","pubTimestamp":1770756113,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nPLX8AA1DA:9","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7501","BK7511","BK7508","BK7067"],"gpt_icon":0},{"id":"2610675197","title":"CSL Ltd - CSL Behring, Second-Half Growth Is Expected to Be Driven by Ig, Albumin and Newly Launched Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2610675197","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610675197?lang=en_us&edition=fundamental","pubTime":"2026-02-11 04:41","pubTimestamp":1770756113,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nPLX8AA1DA:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7508","BK7501","CSL.AU","BK7067"],"gpt_icon":0},{"id":"2610675111","title":"CSL Ltd - Share Buy-Back Expanded From US$500M to  US$750M","url":"https://stock-news.laohu8.com/highlight/detail?id=2610675111","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610675111?lang=en_us&edition=fundamental","pubTime":"2026-02-11 04:41","pubTimestamp":1770756113,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nPLX8AA1DA:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","BK7511","BK7508","CSL.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":142,"code":"91000000","status":"200"}]}}